SAFETY, IMMUNOGENICITY, AND EFFICACY OF INTRAMUSCULAR AND ORAL DELIVERY OF ERA-G333 RECOMBINANT RABIES VIRUS VACCINE TO BIG BROWN BATS (<i>EPTESICUS FUSCUS</i>).

ABSTRACT: Attenuated strains of rabies virus (RABV) have been used for oral vaccination of wild carnivores in Europe and North America. However, some RABV vaccines caused clinical rabies in target animals. To improve the safety of attenuated RABV as an oral vaccine for field use, strategies using selection of escape mutants under monoclonal antibody neutralization pressure and reverse genetics-defined mutations have been used. We tested the safety, immunogenicity, and efficacy of one RABV construct, ERA-g333, developed with reverse genetics by intramuscular (IM) or oral (PO) routes in big brown bats (Eptesicus fuscus). Twenty-five bats received 5×10⁶ mouse intracerebral median lethal doses (MICLD₅₀) of ERA-g333 by IM route, 10 received 5×10⁶ MICLD₅₀

SUBMITTER: Gilbert AT 

PROVIDER: S-EPMC11307205 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature